Location of Repository

Evolving clinical profile of IL-1β, IL-10 and CTLA-4 gene in rheumatoid factor positive Caucasian population

By Int J Cur Bio Med Sci. Varsha Gupta Neelima Singh Sanjeev kumar Singh Ajay kumar Singh Anupama Sharma

Abstract

Rheumatoid arthritis (RA), a systemic autoimmune condition, causes joint damage and sometimes extra-articular lesions (cutaneous vasculitis, neuropathy, Felty’s syndrome, pericarditis, intersticial lung disease) that may be life threatening. The reason why extra-articular features will develop in rare RA patients is unknown. Our study was aimed to find any disease correlation with respect to a few genetic loci implicated in rheumatoid arthritis. In our study no significant association was observed for Il-1β and IL-10. However CTLA-4 showed polymorphism in RA and controls. In our earlier article we reported polymorphism of HLA-DRB1 in Caucasian population. The study was conducted on 60 patients, where 30 were control and 30 were diseased. All the patients selected for the study were Rf (rheumatoid factor) positive. Therefore the studies need to be conducted on larger group of patients, so that the association can be verified in Caucasian population (Indian scenario)

Topics: JOURNALS
Publisher: CurrentSciDirect Publications
Year: 2011
OAI identifier: oai:cogprints.org:7316
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://cogprints.org/7316/1/Ev... (external link)
  • http://cogprints.org/7316/ (external link)
  • Suggested articles

    Preview

    Citations

    1. (1996). 85(3):307–310. Anupama Sharma et al.
    2. (2000). A single nucleotide polymorphism in exon 1 of Cytotoxic T-lymphocyteassociated-4 (CTLA-4) is not associated with rheumatoid arthritis. Rheumatology.
    3. (2002). An association between the CTLA-4 exon1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. J Rheumatol.
    4. (2001). Aregulatory role for cytoplasmicYVKM motif in CTLA-4 inhibition of TCR signaling.
    5. (2003). Association of CTLA4 gene A-G polymorphism with rheumatoid arthritis in Chinese. Clin Rheumatol.
    6. (2003). Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease.
    7. (1999). Complete sequence determination of the mouse and human CTLA4 gene loci: crossspecies DNA sequence similarity beyond exon borders. Genomics.
    8. (2000). CTLA-4 gene polymorphism in Japanese patients with rheumatoid arthritis. J Rheumatol.
    9. (2006). CTLA-4 lacking the cytoplasmic domain costimulates IL-2 production in T-cell hybridomas. Immunol Cell Biol.
    10. (1998). CTLA4 codon 17 dimorphism in patients with rheumatoid arthritis. Tissue Antigens.. doi
    11. (2007). Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev.
    12. (1994). Divergent T-cell cytokine patterns in inflammatory arthritis.
    13. Immuneinteractions withCD4_T cellspromote the development of functional osteoclasts from murine CD11c_dendritic cells.
    14. (2003). New concepts in the treatment of rheumatoid arthritis. Annu Rev Med.
    15. (2002). No association of polymorphisms of the CTLA-4 exon 1(+49) and promoter (-318) genes with rheumatoid arthritis in the Korean population. Scand J Rheumatol . doi
    16. (2000). Physiologic role of interleukin-1receptor antagonist. Arthritis Res.
    17. (2001). Polymorphism in codon 17 of the CTLA-4 gene (+49 A/G) is not associated with susceptibility to rheumatoid arthritis in British Caucasians. Tissue Antigens. doi
    18. (1996). Role of cytokines in rheumatoid arthritis. Annu Rev Immunol.
    19. (2007). T cell costimulation: a rational target in the therapeutic armamentarium for autoimmune diseases and transplantation. Annu Rev Med.
    20. (1997). The emerging role of CTLA-4 as an immune attenuator. Immunity.
    21. (2005). The PTPN22R620W polymorphism associates with RF+ rheumatoid arthritis in a dose dependent manner but not with HLA-SE status. Genes Immun. doi
    22. (2008). The reverse stop-signal model for CTLA4 function. Nat Rev.
    23. (2002). Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis Rheum.
    24. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum.1998;
    25. (2005). Tumour necrosis factor alpha antagonists and early postoperative complications in patients with inflammatory joint disease undergoing elective orthopaedic surgery. Ann Rheum Dis.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.